German medicine price bill edges forward
This article was originally published in Scrip
Executive Summary
A German bill that would see pharmaceutical companies negotiate medicine prices on the basis of their benefit is edging closer to law after the German cabinet approved it on 29 June. The same bill also includes a measure that will oblige companies to publish Phase III clinical trial results.